ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Paraplatin (Carboplatin) Alimta (Pemetrexed) EP=Moderate; FN> J Clin Onc 27: 3284, 2009<strong>Clinical</strong> Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Note: Treatment for PS≥3 will be considered off pathway.Non-Small Cell Lung (NSCL): Third Line MetastaticChemotherapy:Taxotere (Docetaxel) EP=Low; FN=10%-20%Docetaxel 75mg/m 2 D1q 21 Day Cycle>> J Clin Oncol 18:2354-2362, 2000Navelbine (Vinorelbine) EP=Minimal; FN> J Clin Oncol 18:2354-2362, 2000Gemzar (Gemcitabine) EP=Low; FN> J Clin Oncol 23:8380-8388, 2005Alimta (Pemetrexed) EP=Low; FN> J Clin Oncol 22:1589-1597, 2004>> J Clin Oncol 26:3543-3551, 2008Tarceva (Erlotinib)Erlotinib 150mg PO q D>> N Engl J Med 353:123-132, 2005Taxol (Paclitaxel) EP=Low; FN=10%-20%Paclitaxel 80mg/m2 D1, D15, D21q 28 Day Cycle>> <strong>Cancer</strong>1997;79:724-729Page 29 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language